Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.0060.000112%
Carotid artery occlusion24.04.06.008; 17.08.01.0120.000302%Not Available
General physical health deterioration08.01.03.0180.001455%Not Available
Tachyarrhythmia02.03.02.0080.000112%Not Available
Lhermitte's sign17.02.06.014--Not Available
Left ventricular dysfunction02.04.02.0110.000168%
Tumour haemorrhage24.07.01.028; 16.32.03.0080.000280%
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000112%Not Available
Dry gangrene24.04.03.018; 23.06.06.0030.000112%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000112%Not Available
Subileus07.13.01.0040.000112%Not Available
Ventricular hypokinesia02.04.02.0130.000224%Not Available
Suprapubic pain08.01.08.0170.000168%Not Available
Hypocalciuria20.02.01.030; 14.04.01.0140.000112%Not Available
Deep vein thrombosis24.01.02.0030.002183%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000112%Not Available
Catheter site haemorrhage24.07.01.003; 12.07.02.002; 08.02.02.0020.000112%Not Available
Facial paresis17.04.03.0020.000168%
Malignant neoplasm progression16.16.01.0050.002183%Not Available
Enterocutaneous fistula23.07.04.017; 07.11.05.0050.000112%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000504%Not Available
Necrotising colitis07.08.01.0130.000168%Not Available
Metastases to peritoneum16.22.02.008; 07.21.03.0030.000112%Not Available
Eye oedema06.08.03.0130.000112%Not Available
Catheter site pain08.02.02.004; 12.07.02.0040.000112%Not Available
Diastolic dysfunction02.04.02.0220.000112%Not Available
Deafness bilateral04.02.01.0070.000392%Not Available
Fanconi syndrome acquired20.05.03.012; 14.01.01.0130.000336%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.001254%Not Available
Febrile bone marrow aplasia01.03.03.007; 08.05.02.0050.000448%Not Available
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene